1. | kschaver | |
2. | sdal3584 | |
3. | swedencup494 | |
4. | ghostgt | |
5. | dacguvnor |
1. | kschaver | |
2. | sdal3584 | |
3. | swedencup494 | |
4. | ghostgt | |
5. | dacguvnor |
1. | sdal3584 03/05/2018 up 33.9% Nice! |
2. | kschaver 01/26/2018 Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
3. | kschaver 03/05/2018 Announced that the initial patient successfully completed the first cycle 1 of treatment in its Phase 1b/2 m… |
4. | kschaver 02/12/2018 Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium |
5. | kschaver 04/19/2018 Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine |
6. | sdal3584 06/08/2018 Trovagene (TROV): Shoring up the Balance Sheet by Selling Shares Comes with a Price |
7. | kschaver 02/07/2018 Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML) |